Areas of Focus

Oncology and Inflammation



Our proprietary toxin, PH-1 or Thailanstatin (a spliceosome modulator) is being used to generate our first pipeline of novel ADC product candidates to address unmet needs in cancer patients with improved efficacy and differentiated safety relative to traditional ADC-based therapies. PH-1 targets proper splicing of introns resulting in mRNA decay depriving cancer cells of thousands of essential proteins vital to the survival and proliferation of cancer cells. In addition, PH-1 creates mis-spliced proteins or neoepitopes which the immune cells can target well after the initial payload is delivered, in essence creating a second mechanism for cancer killing. Our first product candidate is an ADC targeting Trop2, which is an antigen broadly expressed in solid tumors of epithelial origin.


Our lead product candidate, PHP- 303 is an oral, once daily, potent, selective small molecule inhibitor of neutrophil elastase (NE) designed to inhibit the bioactive form of NE that Peak Bio is developing for the treatment of alpha1 anti-trypsin deficiency (AATD), a potentially life-threatening rare, genetic condition that results in severe debilitating diseases, including early-onset pulmonary emphysema. Also, PHP-303 is being explored in animal models of COVID-19-related acute respiratory distress syndrome (ARDS). Peak Bio has non-dilutive pre-clinical grant from the Department of Defense (DoD) to explore this indication.